IMM 1.72% 29.5¢ immutep limited

cvac and stimuvax - some perspective.

  1. 104 Posts.
    lightbulb Created with Sketch. 109
    While both Cvac and Stimuvax target MUC-1, they have at least one key difference. Cvac is a personalised vaccine (like Dendreon's Provenge), whereas Stimuvax is an off-the-shelf product. Personalised vaccines are believed to work better.

    The link below provides a thorough analysis into the Stimuvax trials to date (the reader comments on the article are enlightening as well). I do hope that the Stimuvax phase 3 trial is successful, however there is a real possibility that it may not be. If it fails, then I hope that the market realises that that does not mean that Cvac will automatically be a failure as well. Cvac's technology is different and its phase 2 results, I believe, offer a better likelihood of success.

    http://www.thestreet.com/story/11179526/1/oncothyreon-deep-dive-into-stimuvax.html
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
(20min delay)
Last
29.5¢
Change
0.005(1.72%)
Mkt cap ! $428.5M
Open High Low Value Volume
28.5¢ 30.5¢ 28.5¢ $469.8K 1.579M

Buyers (Bids)

No. Vol. Price($)
9 297652 29.0¢
 

Sellers (Offers)

Price($) Vol. No.
30.0¢ 7500 2
View Market Depth
Last trade - 16.10pm 19/07/2024 (20 minute delay) ?
IMM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.